HIG Capital completed the acquisition of a majority stake in Aspire Pharma from Juno Pharmaceuticals for $298m.

HIG Capital, an investment firm, completed the acquisition of a majority stake in Aspire Pharma, a provider of niche generic and branded specialty pharmaceuticals, for $298m. Juno Pharmaceuticals, a biopharmaceutical company, will divest its stake. “We are delighted to be supporting Graham and his team to further build upon Aspire’s success. The Company’s track record of identifying, developing and launching niche pharmaceutical products, coupled with H.I.G.’s international presence and history of supporting organic and acquisitive growth in its portfolio companies, underpins an exciting next chapter for Aspire,” John Harper, HIG Capital Managing Director.